sb 206553 has been researched along with Serotonin Syndrome in 2 studies
SB 206553: a high-affinity 5-HT(2C/2B) antagonist; structure given in first source
Serotonin Syndrome: An adverse drug interaction characterized by altered mental status, autonomic dysfunction, and neuromuscular abnormalities. It is most frequently caused by use of both serotonin reuptake inhibitors and monoamine oxidase inhibitors, leading to excess serotonin availability in the CNS at the serotonin 1A receptor.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shumsky, JS | 1 |
| Kao, T | 1 |
| Amato, N | 1 |
| Simansky, K | 1 |
| Murray, M | 1 |
| Moxon, KA | 1 |
| Morley, KC | 1 |
| Arnold, JC | 1 |
| McGregor, IS | 1 |
2 other studies available for sb 206553 and Serotonin Syndrome
| Article | Year |
|---|---|
Partial 5-HT(1A) receptor agonist activity by the 5-HT(2C) receptor antagonist SB 206,553 is revealed in rats spinalized as neonates.
Topics: Animals; Animals, Newborn; Behavior, Animal; Disease Models, Animal; Female; Indoles; Male; Motor Ac | 2005 |
Serotonin (1A) receptor involvement in acute 3,4-methylenedioxymethamphetamine (MDMA) facilitation of social interaction in the rat.
Topics: Animals; Hallucinogens; Indoles; Interpersonal Relations; Ketanserin; Male; N-Methyl-3,4-methylenedi | 2005 |